LeonaBio, Inc., was incorporated as M3 Biotechnology, Inc., in Washington State on March 31, 2011, and was re-registered as a joint stock company in Delaware on October 27, 2015. The company is an late-stage clinical biopharmaceutical company that develops small drug molecules to restore neuronal health and stop neurodegeneration. Its lead drug candidates, lasofoxifene and ATH-1105, are novel small molecule therapies designed to target devastating diseases for which current treatment options are limited or ineffective. LeonaBio adheres to the pursuit of scientific excellence and patient-centered innovation, and is committed to developing meaningful new therapies for those who need help the most.
